Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKesson
Fuji
US Department of Justice
UBS
Colorcon
Cerilliant
Argus Health
Accenture

Generated: June 20, 2018

DrugPatentWatch Database Preview

Deutetrabenazine - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for deutetrabenazine and what is the scope of deutetrabenazine freedom to operate?

Deutetrabenazine
is the generic ingredient in one branded drug marketed by Teva Branded Pharm and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Deutetrabenazine has twenty-nine patent family members in eleven countries.

One supplier is listed for this compound.
Summary for deutetrabenazine
International Patents:29
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 9
Clinical Trials: 6
Patent Applications: 8
DailyMed Link:deutetrabenazine at DailyMed
Synonyms for deutetrabenazine
(3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
(3RS,11Brs)-9,10-di((2H3)methoxy)-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-benzo(a)quinolizin-2-one
[2H6]-(+)-Tetrabenazine|||[2H6]-(+)- 9,10-Dimethoxy-1,3R,4,6,7,11bR-hexahydro-3-isobutyl-2H-benzo[a]quinolizin-2-one
1392826-25-3
2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d3)-3-(2-methylpropyl)-, (3R,11bR)-rel-
Austedo
CHEMBL3137326
D10701
DB12161
Deutetrabenazine (USAN/INN)
Deutetrabenazine [USAN:INN]
Dutetrabenazine
GTPL8707
HY-B0590S
Ro 1-9569 D6
SCHEMBL13321841
SCHEMBL16227993
SCHEMBL16228022
SD 809
SD-809
SD809
Tetrabenazine D6
UNII-P341G6W9NB component MKJIEFSOBYUXJB-VFJJUKLQSA-N
UNII-P341G6W9NB component MKJIEFSOBYUXJB-WEZHFFAMSA-N

US Patents and Regulatory Information for deutetrabenazine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-001 Apr 3, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-001 Apr 3, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-001 Apr 3, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-002 Apr 3, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for deutetrabenazine

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,346,800 Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Fuji
US Army
Medtronic
Mallinckrodt
Dow
Federal Trade Commission
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.